EGFR and non-small cell lung carcinoma: Other studies evaluated germline genetic polymorphisms as predictors of response to EGFR-TKIs, showing that genetic polymorphisms of EGFR and downstream PI3K/AKT signaling pathways may be surrogate biomarkers of EGFR-TKI activity and toxicity in NSCLC patients [45–48].